Abstract: Cytochrome P450 3A4 (CYP3A4) is quantitatively the most important P450 enzyme in adults. It is suggested that CYP3A4 genetic polymorphisms may influence the rate of the metabolism and elimination of CYP3A4 substrates in human beings. Ibrutinib is an anticancer drug and primarily metabolized by CYP3A4. The aim of this study was to systematically investigate the effects of 22 CYP3A4 protein variants on the metabolism of ibrutinib in vitro. When compared with wild-type CYP3A4.1, two variants (CYP3A4.17 and CYP3A4.24) had no detectable enzyme activity; five variants (CYP3A4.10, .11, .18, .23 and .33) exhibited no significant differences; another five variants (CYP3A4.3, .4, .9, .19 and .34) showed increased intrinsic clearance values, while the remaining nine variants (CYP3A4.2, .5, .14, .15, .16, .28, .29, .31 and .32) displayed decreased enzymatic activities in different degrees. As the first study of 22 CYP3A4 protein variants in ibrutinib metabolism, these comprehensive data may help in the clinical assessment of the metabolism and elimination of ibrutinib and also offer a reference to the personalized treatment of ibrutinib in clinic.
Ibrutinib (also called PCI-32765), an orally active inhibitor of Bruton's tyrosine kinase (BTK), has been recently approved for treating B-cell malignancies, such as chronic lymphocytic leukaemia, mantle cell lymphoma and Waldenström's macroglobulinaemia [1] . After oral administration, it is completely absorbed and mostly metabolized in the liver by cytochrome P450 3A4 (CYP3A4) [2] . As the metabolite of ibrutinib, PCI-45227 has an inhibitory activity towards BTK approximately 15 times lower than that of ibrutinib [3] . Previous literatures had reported that drug-drug interactions (DDIs) may occur when ibrutinib is co-administered with potent CYP3A4 inhibitors or inducers, which affect ibrutinib exposure and its metabolite [4] [5] [6] [7] .
CYP3A4, one of the highest abundant CYP450 enzymes in human liver, metabolizes >50% of the clinical drugs, such as immunosuppressants (tacrolimus), cardiovascular drugs (verapamil) and antidepressants (sertraline) [8, 9] . Recently, more and more evidence has shown that CYP3A4 genetic polymorphisms could affect the large interindividual variation in enzyme activity and result in unpredictable adverse side effects [10, 11] . So far, there are 53 CYP3A4 allelic variants in total in the Human CYP Allele Nomenclature Committee website (http://www.cypalleles.ki.se/cyp3a4.htm). Among them, seven novel alleles CYP3A4*28-*34 newly named by the Human CYP Allele Nomenclature Committee were found by Hu et al. [12] , who sequenced the promoter and exons of the CYP3A4 gene in 1114 unrelated Han Chinese individuals recently. And the frequencies of CYP3A4*28-*34 were all 0.04% in Chinese individuals, while CYP3A4*18 was detected at a frequency of 1.26%.
Gene polymorphisms of CYP3A4 could change the enzyme activity and cause adverse effects and therapeutic failures, thus more attention should be paid to the CYP3A4 polymorphisms. Moreover, given the prominent role of CYP3A4 in ibrutinib metabolism, it is essential to understand the effects of CYP3A4 protein variants on the metabolism of ibrutinib, which not only can affect drug metabolism and clearance but also can alter its safety and efficacy profile. In this study, we aimed to determine the metabolite of ibrutinib generated by CYP3A4 enzyme and investigate the catalytic activities of wild-type CYP3A4.1 and 21 CYP3A4 protein variants (15 variants were previously reported, and six novel variants were newly found) on the ibrutinib metabolism in vitro.
Materials and Methods

Chemicals and materials.
Ibrutinib (>98% purity) and its metabolite PCI-45227 (>98% purity) were obtained from Beijing Sunflower Technology Co., Ltd (Beijing, China). The reduced nicotinamide adenine dinucleotide phosphate (NADPH) and carbamazepine (internal standard, IS) were purchased from Sigma (St. Louis, MO, USA). P450 cytochrome b5 and recombinant human CYP3A4 microsomes were kind gifts from Beijing Hospital (Beijing, China). HPLC-grade acetonitrile and methanol were obtained from Merck (Darmstadt, Germany). Ultrapure water was freshly purified by a Milli-Q A10 System (Millipore, Bedford, MA, USA). All of the other chemicals and solvents were of analytical grade commercially available.
Incubation conditions. Incubation mixtures were prepared in a total volume of 200 lL, which included 5 pmol wild-type CYP3A4.1 or other CYP3A4 recombinant variants, 2 pmol purified cytochrome b5, 100 mM potassium phosphate buffer (pH 7.4) and 5-200 lM ibrutinib. The total concentration of DMSO in the mixture was <0.5%. After pre-incubation for 5 min. at 37°C in a Fisher shaking water bath, 10 lL of 1 mM NADPH was added to start the reaction and then continue to incubate for 40 min. at 37°C. Incubations in tubes were finished by cooling to À80°C immediately. Then, 400 lL cool acetonitrile and 25 lL of 1.0 lg/mL IS were added to the incubation mixture. After vortexing for 2 min., the samples were centrifuged at 15,000 g for 10 min. at 4°C. The supernatant of each tube was 1:1 diluted with ultrapure water, and 2 lL was injected into the ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) for analysis. In the experiment, all incubations were carried out in triplicate and kept parallel.
Chromatographic and mass detection conditions. Chromatographic separation was conducted on an Acquity BEH C18 column (2.1 mm 9 50 mm, 1.7 lm). Quantitation was achieved using a XEVO TQD triple quadruple mass spectrometer via an electrospray ionization (ESI) source (Waters Corp.). Detection of the ions was employed in multiple reaction monitoring (MRM) mode, by monitoring the transitions of m/z 475.0?304.2 for PCI-45227 and m/z 237.1?194.2 for IS, respectively. The limit of quantification (LOQ) value of PCI-45227 was 0.01 lM. Both intraday and interday precisions were below 15%, and accuracy was within AE15%; this bioanalytical method was proved to be precise and accurate. Under above conditions, PCI-45227 and IS were well separated and their retention times were 1.57 and 1.46 min, respectively. The Masslynx 4.1 software (Waters Corp., Milford, MA, USA) was used for data acquisition and instrument control.
Statistical analysis.
Michaelis-Menten analysis (Substrate versus Velocity) was estimated using GraphPad Prism 5 (GraphPad Software Inc., SanDiego, CA, USA) by non-linear regression curve fitting. And enzyme kinetic parameters (K m and V max ) for each variant are presented as the mean AE standard deviation (SD) of three parallel experiments. The intrinsic clearance (CL int ) was determined as the ratio of V max /K m . Statistical analysis was carried out with the Statistical Package for the Social Sciences (version 17.0; SPSS Inc., Chicago, IL, USA). One-way analysis of variance (ANOVA) was used for intergroup comparison, and post hoc Dunnett's test was used to analyse differences in catalytic activity between wild-type and other variants. p < 0.05 was considered to be statistically significant.
Results
To obtain the most comprehensive data of CYP3A4 variants on the catalytic activities of ibrutinib in Chinese population, the wild-type CYP3A4.1 and 21 protein variants were assessed in our study. The ratio of V max /K m indicates the intrinsic clearance (CL int ), which can make the enzymatic activity of each CYP3A4 variant have the same evaluation criteria. Michaelis-Menten plots of ibrutinib for the tested 22 CYP3A4 protein variants are shown in fig. 1, and 
Discussion
CYP3A4 is generally believed to be the most abundant enzyme in liver and responsible for the metabolism of approximately half of all clinical drugs, environmental chemicals and steroids [13] . It is clear that CYP3A4 plays a very important role in drug metabolism and exhibits significant variation in enzyme activity. More and more evidence indicates that CYP3A4 genetic polymorphisms could change the pharmacokinetics of its substrate drugs in clinic, which may result in side effects or therapeutic failures [14] [15] [16] . Therefore, it is of great importance to functionally characterize the enzymatic activities of CYP3A4 variants in the metabolism of clinic drugs in vitro.
Ibrutinib, a first-in-class, oral covalent inhibitor of BTK, was recognized by the FDA as a breakthrough therapy and granted accelerated approval for patients with mantle cell lymphoma (in November 2013) and chronic lymphocytic leukaemia (in February 2014) [17, 18] . The most common adverse events of ibrutinib were diarrhoea and stomatitis, neutropenia, anaemia and rash [19, 20] . Thus, the effects of CYP3A4 polymorphisms on ibrutinib metabolism in vitro have a great significance for the clinical research, and these findings may greatly contribute to the development of personalized treatment for the Chinese Han population. In the present study, we used the enzymatic activity of CYP3A4.1 as the positive control. As the results, most CYP3A4 variants exhibited lower enzymatic activity than CYP3A4.1, including CYP3A4.2, .5, .14, .15, .16, .28, .29, .31 and .32. For CYP3A4.2 and CYP3A4.16 variants, our results were the same with the literature, which exhibited lower metabolic activity in midazolam, testosterone and nifedipine compared with CYP3A4.1 [21] . Similarly, CYP3A4.5 showed lower clearance value in ibrutinib metabolism, such as 6b-hydroxycortisol [22] . While CYP3A4.14 and CYP3A4.15 were found not to show low activity in vivo by Lamba and colleagues [23] , this is different from our data. In our system, both variants exhibited lower metabolic activity for ibrutinib in vitro. However, CYP3A4.3, .4, .9, .19, and .34 showed significantly increased enzymatic activity in ibrutinib metabolism. For CYP3A4.3, .9, and .19, three articles reported that there were no significant differences from CYP3A4.1 for testosterone, chlorpyrifos and nifedipine metabolism [24] [25] [26] . Except for CYP3A4.34, CYP3A4.4 was considered to be a decreased-function variant [27] . Although these reports were different from our results, CYP3A4 had substrate-specific alterations in metabolic activity, and amino acid substitutions in these sites might have different impacts for CYP3A4 different substrates [28] .
CYP3A4.10, .11, .18, .23 and .33 exhibited no significant changes in V max /K m values for ibrutinib metabolism, because their V max and K m values increased at the same time. Consequently, the enzymatic activities of CYP3A4.10, .11, .18, 23 and .33 to metabolize ibrutinib were not significantly different from those of CYP3A4.1. Previous reports showed that CYP3A4.10 and CYP3A4.18 exhibited no changes for testosterone and nifedipine, respectively [25, 26] , while the same result was found for CYP3A4.33 [12] . On the contrary, CYP3A4.11 expressed at significantly lower enzymatic activity for testosterone when compared with CYP3A4.1 [25] , which was different from our results. However, it should be noted that CYP3A4 protein variant is frequently dependent on the substrate used.
Interestingly, CYP3A4.17 and CYP3A4.24 exhibited no enzymatic activity in ibrutinib metabolism. Although previous studies reported that CYP3A4.17 produced an amino acid substitution of F189S in exon 7 and exhibited lower catalytic activity for testosterone, chlorpyrifos and nifedipine [24, 26] , the metabolite PCI-45227 could not be detected in our study and it showed no catalytic activity towards ibrutinib. In addition, the enzymatic activity of CYP3A4.24 was assessed for the first time and showed no catalytic activity in ibrutinib metabolism.
Overall, our findings provide strong evidence that CYP3A4 genetic polymorphisms play a very important role in the metabolism of ibrutinib. Indeed, although most of CYP3A4 variants are rare, these variations can lead to different responses to human drugs that are substrates for CYP3A4. In clinic, rare CYP3A4 variants might not explain the whole reason for large interindividual variation, while they are important to predict the risk of DDIs for individuals that carry them. This conclusion has strong implications for the prediction of complex pharmacogenetics in the context of precision medicine initiatives.
In summary, our study provides functional assessment of 22 CYP3A4 variants on the metabolism of ibrutinib in vitro for the first time. Our data revealed that most of these tested variants exhibited significantly decreased catalytic activities or no activities towards ibrutinib, which may offer a reference to the personalized medication of ibrutinib in clinical practice. As the first study of all aforementioned variants in ibrutinib metabolism, further research should be carried out to confirm the functional and clinical impacts of these variants for ibrutinib.
